Efficacy and safety of ciprofol versus remimazolam combined with alfentanil for sedation during outpatient colonoscopy: a randomized double-blind noninferiority
trial

Xuan Liu; Qianqian Tang; Ning Zou; Changming Wang; Xuejun Guo

doi:10.1016/j.bjane.2026.844824

Estudo Original

Efficacy and safety of ciprofol versus remimazolam combined with alfentanil for sedation during outpatient colonoscopy: a randomized double-blind noninferiority trial

Xuan Liu, Qianqian Tang, Ning Zou, Changming Wang, Xuejun Guo

http://dx.doi.org/10.1016/j.bjane.2026.844824 Braz J Anesthesiol, Ahead of Print, 2026

PDF

Downloads: 1

Abstract

Introduction

Colonoscopy often causes significant discomfort to patients. To improve patient experience, sedation-assisted colonoscopy is being increasingly adopted. This study was designed to assess the efficacy and safety of ciprofol versus remimazolam combined with alfentanil during outpatient colonoscopy.

Methods

A randomized, double-blind controlled clinical trial was performed among patients scheduled for elective outpatient colonoscopy. Patients were randomly allocated at a 1:1 ratio to two groups: the ciprofol group (Group C, 0.4 mg.kg^-1 intravenously, n = 88) and the remimazolam group (Group R, 0.3 mg.kg^-1 intravenously, n = 88). Intravenous alfentanil (3 μg.kg^-1) was administered to all patients in conjunction with the study drug. The primary outcome was the success rate of colonoscopy. Secondary outcomes included induction time, discharge time, satisfaction levels (patients and endoscopists), and adverse events.

Results

In the ITT population, colonoscopy success rates were 100.0% (88/88) in Group C and 98.9% (87/88) in Group R (treatment difference [95% CI]: 0.011 [-0.024 to 0.048]). The lower bound of the two-sided 95% CI was above the prespecified noninferiority margin of -0.08, confirming the noninferiority of ciprofol relative to remimazolam. After Bonferroni correction (adjusted threshold p < 0.0028), discharge time was longer in Group C (8.5 [6.0‒12.0] vs. 7.0 [5.0‒9.0] minutes; p = 0.002). Group R showed numerically higher MAP and HR at several time points.

Conclusions

This study demonstrated that intravenous ciprofol (0.4 mg.kg^-1) or remimazolam (0.3 mg.kg^-1), combined with alfentanil (3 μg.kg^-1), provided effective sedation for outpatient colonoscopy.

Keywords

Alfentanil; Ciprofol; Colonoscopy; Conscious Sedation; Gastrointestinal Endoscopy; Remimazolam

Referências

1. Karsenti D, Tharsis G, Burtin P, et al. Adenoma and advanced neoplasia detection rates increase from 45-years of age. WJG. 2018;25:447−56.

2. Gao S-H, Tang Q-Q, Wang C-M, et al. The efficacy and safety of ciprofol and propofol in patients undergoing colonoscopy: A double-blind, randomized, controlled trial. J Clin Anesth. 2024;95:111474.

3. Li J, Wang X, Liu J, et al. Comparison of ciprofol (HSK3486) versus propofol for the induction of deep sedation during gastroscopy and colonoscopy procedures: A multi-centre, noninferiority, randomized, controlled phase 3 clinical trial. Basic Clin Pharma Tox. 2022;131:138−48.

4. Tang L, Ye C, Wang N, et al. The median effective doses of propofol combined with two different doses of nalbuphine for adult patients during painless gastroscopy. Front Pharmacol. 2022;13:1014486.

5. Kumar S, Khuba S, Agarwal A, Gautam S, Yadav M, Dixit A. Evaluation of efficacy of Valsalva maneuver for attenuating propofol injection pain: a prospective, randomized, single blind, placebo controlled study. Korean J Anesthesiol. 2018;71(6):453−8.

6. Luo Z, Tu H, Zhang X, et al. Efficacy and Safety of HSK3486 for Anesthesia/Sedation in Patients Undergoing Fiberoptic Bronchoscopy: A Multicenter, Double-Blind, Propofol-Controlled, Randomized, Phase 3 Study. CNS Drugs. 2022;36(3):301−13.

7. Zhao N, Zeng J, Fan L, et al. Moderate sedation by total intravenous remimazolam-alfentanil vs. propofol-alfentanil for third molar extraction: A prospective randomized controlled trial. Front Med. 2022;9:950564.

8. Zhou Y-Y, Yang S-T, Duan K-M, et al. Efficacy and safety of remimazolam besylate in bronchoscopy for adults: A multicenter, randomized, double-blind, positive-controlled clinical study. Front Pharmacol. 2022;13:1005367.

9. Teng Y, Ou M, Wang X, et al. Efficacy and safety of ciprofol for the sedation/anesthesia in patients undergoing colonoscopy: Phase IIa and IIb multi-center clinical trials. Eur J Pharm Sci. 2021;164:105904.

10. Li D, Wang Y, Xing Y, Zhao Z, Chang L, Leng Y. Effectiveness and safety of remimazolam tosilate versus propofol for sedation in patients undergoing gastrointestinal endoscopy: a randomized controlled trial. Int J Clin Pharm. 2024;46:1371−80.

11. Wang Z, Zhan R, Mo L, et al. Comparison of effect of remimazolam and propofol on respiration of patients under deep sedation for colonoscopy: a prospective multicenter randomized controlled trial. Eur J Med Res. 2025;30:250.

12. Zhu H, Su Z, Zhou H, et al. Remimazolam Dosing for Gastroscopy: A Randomized Noninferiority Trial. Anesthesiology. 2024;140:409−16.

13. Zhou R, Fu L, Liu S, et al. Influences of Propofol, Ciprofol and Remimazolam on Dreaming During Anesthesia for Gastrointestinal Endoscopy: A Randomized Double-Blind Parallel-Design Trial. DDDT. 2024;18:1907−15.

14. Wang L-L, Guan Z-Y, Wang C-M, Zhang Y-W, Zhang J, Zhao P. A comparative study on the efficacy and safety of propofol combined with different doses of alfentanil in gastroscopy: a randomized controlled trial. J Anesth. 2023;37:201−9.

15. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials. Obstet Gynecol. 2010;115:1063−70.

16. Cui X, Cheng Z, Li H, et al. Efficacy and Safety of Different Doses of Remimazolam Tosilate Applied in Upper Gastrointestinal Endoscopy: A Prospective Randomized Controlled Double-Blind Trial. DDDT. 2023;17:2889−96.

17. Pastis NJ, Hill NT, Yarmus LB, et al. Correlation of Vital Signs and Depth of Sedation by Modified Observer’s Assessment of Alertness and Sedation (MOAA/S) Scale in Bronchoscopy. J Bronchology Interv Pulmonol. 2022;29:54−61.

18. Riphaus A, Wehrmann T, Weber B, et al. S3 Guideline: Sedation for gastrointestinal endoscopy 2008. Endoscopy. 2009;41:787−815.

19. Trevisani L. Post-Anaesthetic Discharge Scoring System to assess patient recovery and discharge after colonoscopy. WJGE. 2013;5:502.

20. Stark PA, Myles PS, Burke JA. Development and Psychometric Evaluation of a Postoperative Quality of Recovery Score: The QoR-15. Anesthesiology. 2013;118:1332−40.

21. Zhong J, Zhang J, Fan Y, et al. Efficacy and safety of Ciprofol for procedural sedation and anesthesia in non-operating room settings. J Clin Anesth. 2023;85:111047.

22. Shi W, Cheng Y, He H, et al. Efficacy and Safety of the Remimazolam-Alfentanil Combination for Sedation During Gastroscopy: A Randomized, Double-blind, Single-center Controlled Trial. Clin Ther. 2022;44:1506−18.

23. Pambianco DJ, Borkett KM, Riff DS, et al. A phase IIb study comparing the safety and efficacy of remimazolam and midazolam in patients undergoing colonoscopy. Gastrointest Endosc. 2016;83:984−92.

24. Chen S, Wang J, Xu X, et al. The efficacy and safety of remimazolam tosylate versus propofol in patients undergoing colonoscopy: a multicentered, randomized, positive-controlled, phase III clinical trial. Am J Transl Res. 2020;12(8):4594−603.

25. Liang P, Dai M, Wang X, et al. Efficacy and safety of ciprofol vs. propofol for the induction and maintenance of general anaesthesia: A multicentre, single-blind, randomised, parallel-group, phase 3 clinical trial. Eur J Anaesthesiol. 2023;40 (6):399−406.

26. Wiltshire HR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A Placeboand Midazolam-Controlled Phase I Single Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Remimazolam (CNS 7056): Part II. Population Pharmacokinetic and Pharmacodynamic Modeling and Simulation. Anesth Analg. 2012;115:284−96.

27. Sessler DI, Bloomstone JA, Aronson S, et al. Perioperative Quality Initiative consensus statement on intraoperative blood pressure, risk and outcomes for elective surgery. Br J Anaesth. 2019;122:563−74.

28. Doğanay G, Ekmekci P, Kazbek BK, Yılmaz H, Erkan G, Tüzüner F. Effects of alfentanil or fentanyl added to propofol for sedation in colonoscopy on cognitive functions: Randomized controlled trial. Turk J Gastroenterol. 2017;28:453−9.

29. Yao Y, Guan J, Liu L, Fu B, Chen L, Zheng X. Discharge readiness after remimazolam versus propofol for colonoscopy: A randomised, double-blind trial. Eur J Anaesthesiol. 2022;39:911−7.

30. Doi M, Morita K, Takeda J, Sakamoto A, Yamakage M, Suzuki T. Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallelgroup, phase IIb/III trial. J Anesth. 2020;34:543−53.

Submetido em:
25/04/2026

Aceito em:
05/09/2026